Study Demonstrates Semaglutide Improves Liver Histologic Results in Patients With MASH

Source: Pharmacy Times articles

About 62.9% of patients with metabolic dysfunction–associated steatohepatitis (MASH) receiving semaglutide experienced resolution of steatohepatitis without worsening of fibrosis.
Read More